商务合作
动脉网APP
可切换为仅中文
BRISBANE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced the appointment of Arati V. Rao, M.D., as chief medical officer.
加利福尼亚州布里斯班,2026年11月11日(环球电讯社)——专注于靶向蛋白降解药物的发现、开发和商业化的临床阶段生物制药公司Nurix Therapeutics, Inc.(纳斯达克股票代码:NRIX)今日宣布任命Arati V. Rao医学博士为首席医疗官。
Dr. Rao brings more than 20 years of experience spanning academic hematology and oncology, early- and late-stage clinical development, and global regulatory submissions. She will lead Nurix's clinical development organization as the company advances its registrational program for bexobrutideg and its broader pipeline..
拉奥博士拥有二十余年的丰富经验,涵盖学术性血液学与肿瘤学、早期及后期临床开发以及全球监管申报等领域。随着公司推进贝索布鲁替德(bexobrutideg)的注册申报计划及其更广泛的产品管线,她将领导Nurix公司的临床开发组织。
“Arati brings deep expertise in hematologic malignancies and a record of leading global development programs from clinical investigation through regulatory submission and approval,' said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. 'As we advance bexobrutideg with Roche, her experience will be invaluable in executing our clinical strategy.
“Arati 在血液系统恶性肿瘤领域拥有深厚的专业知识,并在领导全球开发项目方面有着卓越的记录,涵盖从临床研究到监管申报和获批的全过程,”Nurix 公司总裁兼首席执行官 Arthur T. Sands 博士表示。“在我们与罗氏共同推进 bexobrutideg 的过程中,她的经验对于执行我们的临床战略将具有不可估量的价值。”
Arati’s leadership across early- and late-stage development will also help us translate the next generation of Nurix's scientific advances into potential new medicines for patients.”.
Arati在早期和晚期开发阶段的领导能力也将帮助我们将Nurix的下一代科学进展转化为潜在的新药物,造福患者。
“Targeted protein degradation offers a compelling opportunity to develop new treatments for patients whose diseases remain inadequately controlled by existing therapies,' said Dr. Rao. 'Nurix has built a strong scientific foundation and a clinical pipeline with the potential to make a meaningful difference in patients' lives.
“靶向蛋白降解为开发新疗法提供了令人瞩目的机遇,可惠及那些现有疗法未能充分控制疾病的患者,”Rao博士表示。“Nurix已建立起坚实的科学基础,并拥有有望显著改善患者生活的临床管线。”
I look forward to working with the Nurix team, our partners and clinical investigators to advance bexobrutideg and bring additional programs into and through clinical development.”.
我期待与 Nurix 团队、我们的合作伙伴及临床研究者携手,推进 bexobrutideg 的研发,并推动更多项目进入且顺利通过临床开发阶段。
Dr. Rao joins Nurix from Pfizer, where she served as vice president, late-stage clinical development, and most recently as global franchise head for PF-08634404, a PD-1/VEGF bispecific antibody. At Pfizer, she led global, cross-functional development teams and held leadership roles overseeing thoracic oncology and hematology.
Rao博士加入Nurix之前曾在辉瑞公司任职,担任晚期临床开发副总裁,并最近出任PF-08634404(一种PD-1/VEGF双特异性抗体)的全球产品线负责人。在辉瑞期间,她领导了全球跨职能开发团队,并担任领导职务,负责胸科肿瘤学和血液学领域。
Before Pfizer's acquisition of Seagen, she served as Seagen's vice president, early-stage clinical development, overseeing a portfolio of antibody-drug conjugates and immunotherapy programs, as well as external collaborations..
在辉瑞收购Seagen之前,她担任Seagen早期临床开发副总裁,负责管理抗体药物偶联物和免疫疗法项目组合,以及对外合作事务。
Dr. Rao previously served as the clinical development lead for U.S., European and other worldwide regulatory submissions for the CAR T cell therapy Tecartus (brexucabtagene autoleucel) at Kite-Gilead. Her efforts supported its 2020 FDA approval as the first CAR T-cell therapy for adults with relapsed or refractory mantle cell lymphoma..
Rao博士此前在Kite-Gilead担任CAR-T细胞疗法Tecartus(brexucabtagene autoleucel)在美国、欧洲及其他全球监管申报项目的临床开发负责人。她的工作为该疗法于2020年获得美国食品药品监督管理局(FDA)批准提供了支持,使其成为首款用于成人复发性或难治性套细胞淋巴瘤的CAR-T细胞疗法。
Before entering industry, Dr. Rao was an associate professor of medicine at Duke University, where she provided patient care and led NIH-funded clinical and translational research in hematologic malignancies. She has served in leadership and committee roles with organizations including the American Society of Hematology, the American Society of Clinical Oncology and the National Comprehensive Cancer Network.
在加入业界之前,Rao 博士是杜克大学医学系副教授,在那里她提供患者护理并领导由美国国立卫生研究院(NIH)资助的血液系统恶性肿瘤临床与转化研究。她曾在包括美国血液学会、美国临床肿瘤学会和国家综合癌症网络在内的多个组织中担任领导职务和委员会成员。
Dr. Rao earned her medical degree from B.J. Medical College in Pune, India, and completed her internal medicine residency and fellowships in hematology-oncology and geriatrics at Duke University..
拉奥博士在印度浦那的B.J.医学院获得医学学位,并在杜克大学完成了内科住院医师培训以及血液肿瘤学和老年医学的专科进修。
About Nurix Therapeutics
关于 Nurix Therapeutics
Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, a new frontier in drug discovery aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s clinical-stage oncology pipeline includes bexobrutideg, a degrader of BTK being co-developed with Roche, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells.
Nurix Therapeutics 是一家临床阶段的生物制药公司,专注于靶向蛋白降解药物的发现、开发和商业化。这是药物研发的新前沿,旨在改善癌症和自身免疫性疾病患者的治疗选择。Nurix 的临床阶段肿瘤产品管线包括 bexobrutideg(一种与罗氏合作开发的 BTK 降解剂)以及 NX-1607(一种 Casitas B 系淋巴瘤原癌基因 B(CBL-B)抑制剂;CBL-B 是一种 E3 连接酶,可调节包括 T 细胞和自然杀伤(NK)细胞在内的多种免疫细胞的活化)。
Nurix’s autoimmune disease pipeline includes bexobrutideg in collaboration with Roche and a clinical-stage degrader of IRAK4 in collaboration with Gilead. Nurix is also advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates in its wholly owned preclinical pipeline and under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A.
Nurix的自身免疫性疾病产品管线包括与罗氏合作开发的bexobrutideg,以及与吉利德合作开发的处于临床阶段的IRAK4降解剂。Nurix还在其全资拥有的临床前管线中,并通过与吉利德科学公司(Gilead Sciences, Inc.)和赛诺菲(Sanofi S.A.)的合作协议,推进多种潜在的首创或同类最佳降解剂及降解剂抗体偶联药物。
and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements.
以及辉瑞公司,Nurix在其中保留了针对多种候选药物在美国共同开发、共同商业化及利润分成的某些选择权。凭借能够应对几乎任何蛋白质类别的AI集成发现引擎,并结合无与伦比的连接酶专业知识,Nurix的专属团队在将靶向蛋白降解科学转化为临床进展方面建立了强大的优势。
Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in Brisbane, California. For additional information, visit .
Nurix 旨在将基于降解器的疗法置于患者护理的前沿,以全新的方案改写医学篇章,更有效地战胜疾病。Nurix 总部位于加利福尼亚州布里斯班。欲了解更多信息,请访问。
www.nurixtx.com
www.nurixtx.com
.
。
Forward-Looking Statements
前瞻性陈述
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding the expected contributions Dr. Rao will bring to Nurix, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.
本新闻稿包含根据1995年美国《私人证券诉讼改革法》及其他联邦证券法律定义的前瞻性陈述。凡本文件中非描述历史事实的陈述,包括但不限于关于Rao博士预计将为Nurix公司带来的贡献的陈述,均属于前瞻性陈述,涉及可能导致实际结果与此类前瞻性陈述中讨论的结果存在重大差异的风险和不确定性。
Such risks and uncertainties include, among others, the risks described under the heading “Risk Factors” in Nurix’s Quarterly Report on Form 10-Q for the period ended August 31, 2026, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Nurix’s business and results of operations, which could, in turn, have a significant and adverse impact on Nurix’s stock price.
此类风险和不确定性包括但不限于Nurix截至2026年8月31日止季度的10-Q表季度报告“风险因素”标题下所述的风险,以及随后向美国证券交易委员会(SEC)提交的文件中所述的风险。任何这些风险和不确定性都可能对Nurix的业务和经营业绩产生重大不利影响,从而可能对Nurix的股价产生重大且不利的影响。
Nurix cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Nurix undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events..
Nurix 提醒您,不要过度依赖任何前瞻性陈述,这些陈述仅在其作出之日有效。Nurix 没有义务公开更新任何前瞻性陈述,以反映在其作出之日后出现的新信息、事件或情况,或反映意外事件的发生。
Investors and Media
投资者与媒体
Kris Fortner
克里斯·福特纳
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc.
kfortner@nurixtx.com
kfortner@nurixtx.com
A photo accompanying this announcement is available at
随本公告发布的照片可在以下网址获取:
https://www.globenewswire.com/NewsRoom/AttachmentNg/9b845e3c-523a-4a3c-aca9-75f9ac17557d
https://www.globenewswire.com/NewsRoom/AttachmentNg/9b845e3c-523a-4a3c-aca9-75f9ac17557d